Merck KGaA Partners with Hengrui Pharma for Selective PARP1 Inhibitor and Antibody-Drug

By Ashish Tripathi

Pharma Deals Review: Vol 2023 Issue 11 (Table of Contents)

Published: 20 Nov-2023

DOI: 10.3833/pdr.v2023.i11.2837     ISSN: 1756-7874

Section: Licensing



Merck KGaA has entered into an exclusive agreement with Jiangsu Hengrui Pharmaceuticals for ex-China rights to the latter’s HRS-1167 and SHR-A1904...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details